Abstract:Objective To observe the comparison of the therapeutic efficacy of intravitreal of triamcinolone acetonide (TA) for macular edema caused by retinal vein occlusion (RVO) and diabetic retinopathy (DR). Methods TA was injected inttravitreally in 91 eyes of 91 patients with macular edema secondary to RVO and 73 eyes of 67 patients secondary to DR determined by indirect ophthalmoscope, fundus fluorescent angiography (FFA) and optic coherence tomography (OCT). Among the RVO patients, CRVO were 55 eyes (ischemic type was 11 eyes, and 42 eyes were non-ischemic type). BRVO were 36 eyes (ischemic type was 10 eyes, and 26 eyes were non-ischemic type). Among the DR patients, pre-proliferative diabetic retinopathy (PPDR) were 17 eyes and proliferative diabetic retinopathy (PDR) were 56 eyes. The visual acuity, fundus findings, FFA and the macular thickness under the OCT were recorded and analyzed prior to operation and after operation. Follow-up time was 3 months to 1 years. Results In the group of RVO, visual acuity was improved at the end of follow-up in 48 (52.7%) eyes and decreased or unchanged in 4 (4.40%) eyes and 39 (42.9%) eyes, respectively. 50 (54.9%) eyes showed normal macular thickness after injection of TA on OCT. Improved fundus appearance was seen in 27 (29.7%) eyes on OCT. The fundus was unchanged or even worse in 14 (15.4%) eyes on OCT at the last visit. In the group of DR, visual acuity was improved at the end of follow-up in 25 (34.2%) eyes and decreased or unchanged in 3 (4.11%) eyes and 45 (61.6%) eyes, respectively. 24 (32.9%) eyes showed normal macular thickness after injection of TA on OCT. Improved fundus appearance was seen in 22 (30.1%) eyes on OCT. The fundus was unchanged or even worse in 27 (37.0%) eyes on OCT at the last visit. The difference of two groups was significant. In the group of RVO, intraocular pressure was elevated in 24 eyes. Cataract was in 1 eye and endophthalmitis in 1 eye. 8 eyes were injected two times. In the group of DR, intraocular pressure was elevated in 14 eyes. Cataract was in 2 eyes. 9 eyes were injected two times. Conclusions Intravitreal injection of TA is a safe and effective method to the treatment of macular edema secondary to RVO and DR. The therapeutic efficacy for RVO is better than for DR.

Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial

Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study

Comparing the efficacy of dexamethasone implant and anti-VEGF for the treatment of macular edema: A systematic review and meta-analysis

Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis

Safety and Efficacy of Dexamethasone Intravitreal Implant for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in Chinese Patients: Randomized, Sham-Controlled, Multicenter Study

Intravitreal Bevacizumab Treatment for Branch Retinal Vein Occlusion Accompanied by Macular Edema

Comparison of the efficiency of anti-VEGF drugs intravitreal injections treatment with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis

Observation on Intravitreal Injection of Ranibizumab Combined with Laser Photocoagulation for the Treatment of Macular Edema in BRVO

Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema.

Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study

Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience

Triamcinolone As An Adjunct To The Combination Of Anti-Vegf For The Management Of Diabetic Macular Edema

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study

Effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized versus non-vitrectomized eyes: a Meta-analysis

Intravitreal Triamcinolone Versus Bevacizumab for the Treatment of Macular Edema in Retinal Vein Occlusion

Intravitreal Bevacizumab Versus Triamcinolone Acetonide for Macular Edema Due to Branch Retinal Vein Occlusion: a Matched Study.

Bevacizumab Treatment for Acute Branch Retinal Vein Occlusion Accompanied by Subretinal Hemorrhage.

Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Comparision of Intravitreal Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion and Diabetic Retinopathy

Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion